Parkinson’s Institute and Clinical Center partners with CENTOGENE to characterize Parkinson’s patients with targeted gene panel.
For the first time, ever, the Parkinson’s Institute and Clinical Center and CENTOGENE have entered into a collaboration aimed at genetic screening of a large cohort of Parkinson’s patients in the US. Now, individual patients will be screened using a large customized panel carefully selected to identify pathophysiological relevant genetic variants for the development and treatment of Parkinson’s disease.
